Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

FDA Approves Citius Pharmaceuticals' Lymphir (Denileukin Diftitox-cxdl) For R/R Cutaneous T-cell Lymphoma After At Least One Prior Systemic Therapy. This Is The First Indication For Lymphir And The First FDA-approved Product For Citius Pharma

Author: Benzinga Newsdesk | August 08, 2024 07:50am

Posted In: CTXR